Enterprise Value
-88.0M
Cash
208.2M
Avg Qtr Burn
-11.46M
Short % of Float
6.19%
Insider Ownership
2.62%
Institutional Own.
97.06%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
THE-630 Details Solid tumor/s, Cancer, Gastrointestinal stromal tumors | Failed Discontinued |